- PMV Pharmaceuticals Inc (NASDAQ:PMVP) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK) to evaluate PC14586 in combination with Merck’s Keytruda (pembrolizumab) for advanced solid tumors.
- PC14586 is a first-in-class precision oncology small molecule investigational therapy that selectively targets the p53 Y220C mutation.
- PMV Pharma will evaluate PC14586 in combination with Keytruda as a separate arm of the company’s ongoing Phase 1/2 PYNNACLE trial in patients with advanced solid tumors.
- Approximately 36 patients are expected to be enrolled in the combination arm of the trial.
- This combination arm will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PC14586 in combination with Keytruda in patients with advanced solid tumors harboring a p53 Y220C mutation.
- Under the terms of the agreement, PMV Pharma will sponsor the trial, and Merck will supply Keytruda.
- PMV Pharma has conducted a series of experiments to evaluate the combination of p53 Y220C reactivators with checkpoint inhibitors. The combination showed an increase in anti-tumor activity and mean survival time in mouse tumor models, an improvement compared to either agent as monotherapy.
- Price Action: PMVP shares are down 2.55% at $15.56 during the market session on the last check Monday.
Evolus Enters Into Licensing Agreement With Symatese To Exclusively Distribute Next-Generation Dermal Fillers In Europe; Evolus Will Pre-Announce Preliminary, Unaudited Q4 And FY23 Results And Revenue Guidance For 2024 In January
Exclusive Distributor Agreement with Symatese Broadens Evolus' Dermal Filler Footprint Beyond the U.S. to Include the United Kingdom and EuropeEuropean Regulatory Approvals Anticipated in Second Half of 2024Company
